ABSTRACT
INTRODUCTION
Mortality rates from cardiovascular disease are 2 -4 times greater in people with diabetes than those without diabetes, with a similar risk for stroke [1] . Large clinical trials demonstrate that control of glycemic, blood pressure, and lipids [ABCs] leads to risk reduction in cardiovascular events. Indeed, glycemic control led to a 15% -33% risk reduction in the DCCT and UKPDS trials [2] [3] [4] , while maintaining blood pressure with antiotensin converting enzyme inhibitors or blockers resulted in a 16% -50% risk reduction for cardiovascular events in the AS-COT, LIFE, HOPE and MICROHOPE trials [5] [6] [7] [8] . Moreover, controlling lipids, specifically LDL cholesterol, led to a 19% -37% risk reduction in cardiovascular events and stroke as shown in several statin trials [9] [10] [11] [12] [13] .
Despite the evidence for ABC control to reduce the risk of cardiovascular events in large clinical trials, translating these results into real-world clinical practice remains challenging, as demonstrated by national data. Over the past 10 years, only marginal gains in ABC conrol were observed. NHANES demonstrated improvements in glycemic control from 37% to 55.2%, blood pressure from 35.2% to 51%, and LDL from 32.9% to 52.9% over time [14] . Additionally, only 12.7% of people with diabetes in the US achieved all ABC goals simultaneously [15] .
In the age of healthcare reform, where physicians are often evaluated by the proportion of their patients who achieve goal levels, it is critically important to under-stand whether the results demonstrated in large efficacy trials are able to be replicated in real world clinical practice with the same effect. Therefore, we aimed to determine whether glycemic [A1c < 7%], blood pressure [<130/80 mmHg], and cholesterol control [LDL < 100 mg/dL] [ABCs] were associated with incident cardiovascular disease over 10 years in a community-based endocrinology practice. We hypothesize that risk factor control is associated with decreased cardiovascular disease risk over 10 years.
METHODS
The Chesapeake Institutional Review Board reviewed and approved this study. To investigate the effect of ABC control on incident cardiovascular disease [CVD], we employed a non-randomized, retrospective cohort design, where we identified four hundred consecutive patients seen in consultation for diabetes management in a community-based endocrinology practice, beginning in 2000 and followed through 2009. Five patients [1.25%] were excluded for not meeting the most recent ADA diagnostic criteria of diabetes [16] . Data were collected for each individuals' office visits over 10 years [2000] [2001] [2002] [2003] [2004] [2005] [2006] [2007] [2008] [2009] and transcribed into a database for analysis. In order to be included in the analysis cohort for this report, patients had to be18 years or older, had a diagnosis of diabetes [100% diagnosed through ICD-9 codes, problem lists, or lab reports] before or during calendar year 2000, have at least two A1c, blood pressure, and LDL measurements, respectively, and be free of CVD.
CVD was defined as presence of myocardial infarction, stroke, transient ischemic attack, abnormal stress thallium, coronary artery bypass graft [CABG] , congestive heart failure [CHF], cardiac catherization, or stent. 10 patients were excluded for having CVD at baseline. The final sample size for the cohort for these analyses was n = 385. Improvement in risk factor control was defined as moving from "not in goal range" to "in goal range" [A1c < 7%, blood pressure < 130/80 mmHg, LDL < 100 mg/dL] and maintaining that goal throughout the duration of time in the study. The final analysis cohort included 385 patients. No data were self reported.
Patient Management
As previously described [17] , all patients received a detailed physical examination, including a foot exam, at each visit, as part of their ongoing clinical care. Principles of basal/bolus therapy were applied to patients on subcutaneous insulin, insulin pumps, or combination of insulin and oral agents, to target both fasting and postprandial hyperglycemia [18, 19] . The same concept was simulated for patients on secretagogues, leading to use of meglitinides whenever accepted by the patient. Thiazolidinedions and biguanides were used to decrease insulin resistance whenever not contraindicated [4, 20] [ Table  1 ]. Bile acid binding 2.5 [10] Nicotinic acid 0.7 [3] Cholesterol absorption inhibitor 13.5 [53] Copyright © 2013 SciRes.
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Physician charting used a four-page grid system, with medical problems and corresponding actions [prescribing or adjusting medications, instructions on diet, exercise, ordering appropriate labs and referrals to other specialists] in parallel columns. Type of diabetes, duration since diagnosis, A1C, blood pressure, lipid panels, and a complete review of systems were noted at each visit.
Office follow-up was scheduled in 1 -2 months for individuals not meeting all ABC goals and every 3 -4 months for individuals who were meeting all goals. Patients were encouraged to have laboratory work completed 8 -10 days prior to their visit so that those results could be discussed during the office visit. During the office visit, simplified handouts that stated the diabetes national guidelines and their demonstrated risk reductions were given to the patients and discussed with them. A "team of four" philosophy, which included the patient, their family members, physician, and support staff was used to implement intensive therapy to achieve all ABC goals. The team was made aware that sub-optimal participation of any member could impede achievement of goals.
Additionally, patients received a single-page grocery shopping guide that included healthy food choices to encourage achieving satiety using an ad-lib, low-fat, lowglycemic, high fiber diet [21] . They were encouraged to read nutrition labels for calorie, fat, and sugar content and to increase physical activity.
Insulin-requiring patients [type 1 or type 2] were instructed to record blood glucose levels 2 -4 times daily using a grid system to help visualize diurnal and nocturnal patterns. Directions were given on a single sheet with basal therapy and bolus doses using a baseline dose and instructions for correction doses according to a simple sliding scale, adding or subtracting 1 -6 units based on glucose readings. Instructions to use correction doses for prandial insulin to adjust for changes in physical activity, meal size and content were also given. Insulin pump therapy using similar principles was offered to patients with type 1 diabetes based on the physician's assessment of their capabilities [19] . Detailed instructions for preventing and treating hypoglycemia by adjusting the prandial insulin or secretagogue dose or by using simple sugars during an activity were given [22] . Glucose monitoring prior to driving or operating equipment was encouraged. Baseline doses were individualized and adjusted for each patient. All adjustments for prandial insulin, hypoglycemia treatment and prevention were based on an algorithm used in the practice, which was also modified when necessary. Patients using oral agents were instructed to record blood glucose levels at least 2 times daily using a similar grid system. Frequent phone contact with the CBEP [at least one phone call per week] was encouraged for all patients to allow the physician to make adjustments to the treatment regimen when needed in working to eachieve control of the ABCs of diabetes.
Medication Usage
Angiotensin-converting enzyme [ACE] inhibitors [8] and angiotensin receptor blockers [ARBs] [23] were preferentially used for blood pressure control or for treatment of nephropathy. Statins were used in patients with elevated LDL levels whenever possible for their cardiovascular protective effects [9, 24] .
Measures and Study Outcomes
All subjects had height, weight, and blood pressure measured according to standard clinical practice methods. A1c and lipids were collected as part of the patients' routine clinical care through the patients' local hospital or through a commercial lab. CVD was tracked over the entire 10 years period. Medication lists were abstracted from all patient charts. Combination medications were separated into their individual components for purposes of classification.
Statistical Analysis
Measures of central tendency [e.g. proportions, means, standard deviations, medians, etc.] were used for all descriptive analyses. In determining if the proportion of subjects meeting ABC goals increased over time, a chisquare test for trend was used. Stepwise logistic regression was then used as a screening mechanism to identify if differences existed between the proportion of subjects who developed CVD and individual characteristics. Explanatory variables chosen for inclusion were not limited based on statistical significance but were based on literature review and analyses previously conducted in addition to the current analyses. Cox proportional hazards models with time-dependent covariates were used to analyze the effect of ABC control on incident CVD. All models controlled for age, gender, and A1c < 7%, blood pressure < 130/80 mmHg, and LDL < 100 mg/dL, respectively. All analyses were conducted using SAS v.9.3, Cary, North Carolina.
Calculation of sample size was not completed prior to collection of data because the sample was collected for quality assurance/improvement purposes for the practice. However, with 385 subjects, we have 81% power to detect a 50% risk reduction in CVD in individuals who achieve A1c < 7% [α = 0.05].
RESULTS
Population Characteristics
Demographic and clinical characteristics of the cohort [n = 385] are presented in [17] and demonstrated that significantly more patients met the goal of A1C < 7% in the CBEP compared to national estimates [CBEP: 47.1% vs. NHANES 1999-2000: 37%, p = 0.003]. Similar patterns were observed for blood pressure, total cholesterol, and control of all three ABCs.
Incident Cardiovascular Disease and ABC Control
From 2000-2009, 17.6% [n = 68] of patients developed incident CVD. In those who developed CVD, the average time to event was 4.9 ± 3.3 years. There were no statistically significant differences in baseline A1c < 7% between individuals who developed CVD and those who did not develop CVD [ Figure 1 ]. Only slight differences were apparent for LDL < 100 mg/dL, with a greater proportion of individuals with CVD meeting LDL goals levels at baseline. Additionally, a greater proportion of individuals with CVD also had all ABCs in control at baseline in comparison to those without CVD [ Figure 1] .
When the effect of improvement [moving from "not controlled to goal levels" to "controlled to goal levels"] in ABC control on incident CVD was examined, trends in risk reducton were observed for A1c < 7%, blood pressure < 130/80 mmHg, LDL < 100 mg/dL, and all ABCs in control [ 
DISCUSSION
In this 10 year retrospective analysis, which aimed to determine whether glycemic [A1c < 7%], blood pressure [<130/80 mmHg], and lipid control [LDL < 100 mg/dL] [ABCs] was associated with incident coronary heart disease over 10 years in a community-based endocrinology practice, we demonstrated the feasibility of achieving ABC goals above the national average and the significant impact that ABC control has on incident CVD in clinical practice. Additionally, the results demonstrate that the greatest impact in reducing CVD is observed when all three risk factors are controlled.
The results of this report are comparable to the work of others in that goal attainment was similar to the national average for A1c, but subtantially higher for blood pressure, LDL and all ABCs [14] . Although the effect of A1C, LDL and BP control individually, did not show statistically significant risk reduction for CVD, patients with all ABCs in control were 250% less likely to develop incident CVD over time. This is consistent with the 59% relative risk reduction seen in the 13.3 years of follow up in the Steno 2 study, with multifactorial intervention [25] . The lowest incidence of any diabetes related endpoint, was reported in UKPDS 75, when optimal glycemic and blood pressure control was achieved, again demonstrating the importance of achieving control of multiple risk factors [26] . Intensive glycemic control alone, for 3.5 -5.6 years, in the ACCORD, VADT and ADVANCE studies, did not result in risk reduction for cardiovascular events. [27] , again, demonstating the importance for all ABCs to be in control.
In conducting real world research, there are a number of limitations that may effect the results. The data for this report was retrospective and limited to only one community-based endocrinology practice; therefore limiting the generalizability of the results. Additionally, one may argue that as a large proportion of patients had A1c < 7%, rates of hypoglycemia may be high. Every attempt was made to prevent and treat hypoglycemia. Although 47% of our cohort maintained A1C at goal over the 10 years, there was no correlation between frequency of glucose readings < 80 mg/dl and glycemic control [data not shown]. This is in contrast to the 2 -3 times greater incidence of hypoglycemia reported in the intensive arm of ACCORD, ADVANCE, VADT, UKPDS and DCCT trials [2, 4, 27] . The same pattern is evident with weight gain and glycemic control. Unlike the significant weight gain observed in the intensively treated groups in the DCCT, UKPDS, ACCORD and VADT trials [2, 4, 27] weight levels of our patients remained steady over the 10 year study period. Other limitations include the relatively small amount of demographic, behavioral, and psychosocial data collected as part of chart review.
CONCLUSION
Healthcare providers and policy makers increasingly recognize the need for studies that examine long term diabetes management in real world settings, so that effective clinical and policy-level decisions can be made regarding diabetes care. These data provide one of the few reports of the effect of long-term diabetes management on incident CVD in clinical practice. Implementation of models of care that focus on secondary prevention of complications may lead to decreased morbidity and mortality and may have a significant impact in reversing the projected increases in diabetes related complications, mortality, and annual expenditures.
